Activating p53 with a Mutant-Specific Small Molecule

Xijun Zhu,Woong Sub Byun,Dominika Ewa Pienkowska,Kha The Nguyen,Jan Gerhartz,Qixiang Geng,Tian Qiu,Jianing Zhong,Zixuan Jiang,Mengxiong Wang,Roman C. Sarott,Stephen M. Hinshaw,Tinghu Zhang,Laura D. Attardi,Radoslaw P. Nowak,Nathanael S. Gray

DOI: https://doi.org/10.1101/2024.10.23.619961

2024-10-28

Abstract:is the most commonly mutated gene in cancer, but it remains recalcitrant to clinically meaningful therapeutic reactivation. We present here the discovery and characterization of a small molecule chemical inducer of proximity that activates mutant p53. We named this compound TRanscriptional Activator of p53 ( ) due to its ability to engage mutant p53 and BRD4 in a ternary complex, which potently activates mutant p53 and triggers robust p53 target gene transcription. Treatment of p53 expressing pancreatic cell lines with results in rapid upregulation of p21 and other p53 target genes and inhibits the growth of p53 -expressing cell lines. Negative control compounds that are unable to form a ternary complex do not have these effects, demonstrating the necessity of chemically induced proximity for the observed pharmacology. This approach to activating mutant p53 highlights how chemically induced proximity can be used to restore the functions of tumor suppressor proteins that have been inactivated by mutation in cancer.

Cancer Biology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is how to activate the mutant p53 protein (especially the p53Y220C mutant) through the chemical - induced proximity technique. p53 is one of the most commonly mutated genes in tumor suppressor genes. Approximately 50% of cancer patients show somatic mutations of p53 in multiple tumor types. These mutations lead to a decrease in the thermal stability of the p53 protein and/or impaired DNA - binding ability, thereby weakening its tumor - suppressing function. Although there have been many attempts to restore the function of p53, there is currently no method that can be effectively used for clinical treatment.

The paper introduces a small - molecule chemical inducer that can activate the mutant p53. This compound is named TRanscriptional Activator of p53 (TRAP - 1) because it can form a ternary complex with the mutant p53 and BRD4, thereby strongly activating the mutant p53 and triggering the transcription of p53 target genes. Studies have shown that in pancreatic cancer cell lines expressing p53Y220C, treatment with TRAP - 1 can rapidly up - regulate p21 and other p53 target genes and inhibit the growth of these cell lines. The negative control compound (unable to form a ternary complex) does not have these effects, indicating that chemical - induced proximity is necessary for the observed pharmacological effects.

This method not only provides a new idea for activating the mutant p53, but also shows how to use chemical - induced proximity to restore the function of tumor - suppressing proteins inactivated due to mutation. In this way, researchers hope to be able to provide potential treatment options for cancer patients carrying the p53Y220C mutation.